

## DESCRIPTION


<b>Product Name</b>	Anti-human CLDN 18.2 mAb, E9-PE
<b>Product Description</b>	R-Phycoerythrin (PE) conjugated recombinant E9 antibody, human IgG1
<b>Clone Name</b>	E9
<b>Isotype:</b>	Human IgG1
<b>Protein Concentration</b>	0.1 mg/mL
<b>Protein Formulation</b>	Sterile PBS, pH 6.8, 0.1% Na <sub>3</sub>
<b>Storage Condition</b>	< -20°C (Avoid repeated freezing and thawing)
<b>Protein Stability</b>	At least 30 days at 4°C and at least 6 months at -20°C
<b>Applications</b>	Flow cytometry analysis
<b>Recommended usage</b>	1-5ul per staining in 50-100ul volume

## BACKGROUND

Claudin-18 (CLDN18) is a member of a large family of four-span transmembrane proteins called Claudins. These proteins are the essential components of the mammalian tight junctions (TJs) in epithelial cells. Claudin-18 has two splice variants, 18.1 and 18.2. While CLDN18.1 is specifically expressed in the lung tissue, CLDN18.2 expression in normal tissue is more restricted and is only detected in small patches of stomach mucosal. CLDN18.2 expression is elevated in many types of epithelial cancers including stomach, esophagus, pancreatic and ovarian cancers. The expression of CLDN18.2 is not only detected in primary tumors, but also in the metastatic sites. Therefore, CLDN18.2 is an ideal target for monoclonal antibody-based cancer therapies.

## DATA

- A.** Detection of human CLDN18.2 expression on human CLDN18.2-CHO-K1 cells (Cat. #C3011) using recombinant anti-huCLDN18.2 mAbsE9-PE (Cat. #A1013-PE).



Disclaimer: For research use only. Not for use in humans.